Capricor Therapeutics
8840 Wilshire Blvd
2nd Floor
Beverly Hills
California
90211
United States
211 articles about Capricor Therapeutics
-
Capricor Therapeutics to Present Second Quarter 2020 Financial Results and Recent Corporate Update on August 6Company to Host Conference Call and Webcast, August 6, 2020, at 4:30 p.m. ET
7/30/2020
Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that it will release its financial results for the second quarter ended June 30, 2020, after the market close on Thursday, August 6, 2020. Company management will host a conference call and webcast to discuss its financial resul
-
Capricor to Participate in BIO Digital International Convention
6/4/2020
Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today that it will be participating in the upcoming BIO Digital International Convention. Details: Event: BIO Digital 2020 Date: J
-
Capricor to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020
5/26/2020
Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today that Capricor’s CEO, Linda Marbán, Ph.D, will participate on the panel “ Cell therapy for ARDS - When Remdesivir is not enough " hosted by Maxim Group and M-Vest on Wednesday, May 27 beginning at 10:00 a.m. Eastern time (7:00 a
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 26, 2020.
-
Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
5/14/2020
Final Top-Line 12-month Results from Phase II Randomized, Double-blind, Placebo-controlled HOPE-2- Study Demonstrated Improved Performance of Upper Limb (PUL) 2.0 (p=0.05)
-
Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002
5/13/2020
-One-Year Results from Randomized, Double-Blind, Placebo-Controlled Study Demonstrate Improved Performance of Upper Limb (PUL) 2.0 (p=0.05)- -First Ever Study in DMD that Correlates Stabilization in Cardiac Function with a Reduction in a Biomarker of Cell Damage- -Company Planning to Meet with FDA to Discuss Pathway to Approval- -To Host Conference Call and Webcast Today at 8AM ET- LOS ANGELES, May 13, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a
-
New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002U.S. FDA Approves Company’s Expanded Access Protocol to Treat Additional Patients
4/29/2020
Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today new data reporting 100 percent survival in critical COVID-19 patients who were treated with Capricor’s lead asset, off-the-shelf (“allogeneic”) cardiac cell therapy CAP-1002, at Cedars-Sinai Medical Center as part of six compa
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 29, 2020.
-
Capricor Therapeutics to Host Key Opinion Leader Call on Cardiac Complications of Duchenne Muscular Dystrophy
4/13/2020
Capricor Therapeutics today announced that it will host a Key Opinion Leader (KOL) call on the cardiac complications of DMD on Wednesday, April 15, 2020 at 1:30 pm Easter
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 3, 2020.
-
Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine DevelopmentExosomes Platform Technology Expanded to Potentially Combat the Novel Coronavirus
3/24/2020
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today announced that it will host a Key Opinion Leader (KOL) call on why exosomes are uniquely suited for vaccine development on Thursday, March 26, 2020 at 12pm Eastern Time. The call will feature a presentation by K
-
Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products ExpansionCompany Appoints Stephen Gould, Ph.D. as Executive Consultant for its Exosomes Program
3/17/2020
Capricor Therapeutics today announced the expansion of its strategic plan to further develop the company’s exosome platform technologies. In conjunction with these efforts, Stephen Gould, Ph.D. has been appointed as Executive Consultant to gu
-
Capricor Therapeutics Announces Pricing of $5.1 Million Offering Priced At-the-Market
12/17/2019
Each share of common stock offered was sold with a warrant to purchase one share of common stock at an exercise price of $1.10 per share and a five-year term.
-
Capricor Therapeutics has placed a voluntary hold on its Phase II clinical trial for a Duchene Muscular Dystrophy treatment on hold after a patient experienced a severe allergic reaction during dosing.
-
Capricor Therapeutics to Present at 2018 Cell & Gene Meeting on the MesaCompany will Provide Presentation on Cell and Exosome Therapies and Poster on New Research
10/3/2018
Capricor Therapeutics, Inc. will provide a presentation at the 2018 Cell & Gene Meeting on the Mesa today on its cell therapy, CAP-1002, which is currently in clinical development for the treatment of Duchenne muscular dystrophy.
-
Capricor Therapeutics to Present Second Quarter Financial Results and Corporate Update on August 9, 2018
8/2/2018
Capricor Therapeutics will report its second quarter of 2018 financial results and corporate update shortly after the NASDAQ market close on Thursday, August 9. Management will then host a webcast and conference call at 4:30 p.m. ET on August 9.
-
Capricor and USAISR Announce Collaboration to Investigate Exosome Platform to Treat Injured Troops
7/17/2018
Capricor Therapeutics announced it has entered into an agreement with the U.S. Army Institute of Surgical Research (USAISR) to study the potential for the company’s next-generation investigational therapeutic platform, designated CAP-2003
-
Capricor to Give Update on HOPE-2 Clinical Trial for CAP-1002 at International Conference on Duchenne Muscular Dystrophy
2/12/2018
The three-day conference brings together scientists, physicians, companies, patients and their families to discuss the latest developments in Duchenne and Becker muscular dystrophy.
-
Capricor Announces Licensing of Additional Patent Applications From Cedars-Sinai Medical Center for Cellular and Exosome-Based Technologies
1/16/2018
New patent applications pave way for capricor to develop potential new therapeutic platforms for duchenne muscular dystrophy and other disorders.
-
Capricor Therapeutics Announces Issuance of Key U.S. Patent on Exosome Technology
12/13/2017
Capricor today announced that the U.S. Patent and Trademark Office has issued U.S. Patent 9,828,603, which includes composition of matter claims covering cardiosphere-derived cell exosomes.